Israel-based late-clinical stage biotechnology company NeuroSense Therapeutics Ltd (Nasdaq: NRSN) announced on Tuesday that it has received a pivotal patent from the United States Patent and Trademark Office (USPTO) for the novel formulation of PrimeC, its leading drug candidate for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Entitled 'Compositions comprising Ciprofloxacin and Celecoxib' (US Patent No. US 12,097,185), the newly granted patent is expected to extend PrimeC's patent protection by an additional four years, until 2042.
PrimeC includes ciprofloxacin and celecoxib, two FDA-approved compounds in unique doses, formulated in a technology of slow release to synchronise their pharmacokinetic (PK) profiles and enhance their therapeutic synergy. This approach is designed to optimise the treatment efficacy in slowing ALS progression.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals